

**ADDENDUM AND AMENDMENT
TO DEFERRED PROSECUTION AGREEMENT**

The United States Attorney's Office, by its attorney, Leah B. Foley, United States Attorney for the District of Massachusetts (the "Office"), and defendant Magellan Diagnostics, Inc. ("Magellan" or the "Company") hereby enter into this Addendum and Amendment (the "Amendment") to the Deferred Prosecution Agreement ("DPA" or the "Agreement") presently in effect between the parties. *See* Case No. 24-cr-10144-PBS, Dkt. No. 4. The terms and conditions of this Amendment are as follows:

1. Pursuant to Paragraph 3 of the DPA, the Office and the Company agree to extend the term of the Agreement by a period of six months from January 6, 2027 to July 6, 2027. Unless expressly addressed herein, all other terms and conditions of the DPA—including, but not limited to, those relating to Magellan's engagement of an independent compliance monitor (the "Monitor") and continued implementation of a compliance and ethics program designed to prevent and detect violations of the Food, Drug, and Cosmetic Act ("FDCA"), 21 U.S.C. § 301 *et seq.* and its associated regulations—will remain in full force and effect until July 6, 2027.

2. The Office remains free to impose an additional extension of up to six months of the term of the DPA pursuant to Paragraph 3 of the Agreement, for up to a total extension of the term of one year, and without prejudice to the Office's right to proceed as provided in Paragraphs 20–23 of the DPA.

3. Paragraphs 3, 17, and 32 of the DPA, as well as Paragraph 1 of Attachment D thereto, are hereby amended to strike all references to 24 months and replace such references with "30 months." In addition, all references to the term of the Agreement and/or the term of the monitorship contained in the DPA and the attachments thereto shall now be understood to refer to

a 30-month, as opposed to a 24-month, term, ending 30 months from the date on which Magellan retained the Monitor.

4. Pursuant to Paragraph 17 of the DPA, the Monitor's role as claims administrator of the Victim Compensation Fund shall continue for a 36-month period as set forth in Attachment F to the Agreement.

5. Under Paragraph 32 of the DPA, Magellan's publication of the Information and the Agreement on the Company's website shall be updated to include a copy of this Amendment.

6. Pursuant to Paragraph 19 of Attachment D to the DPA, the Monitor shall undertake a second follow-up ("third") review and prepare and submit to the Board of Directors of the Company and the Office a third report following the procedures described in Paragraphs 16–19 of Attachment D.

7. Pursuant to Paragraph 25 of Attachment D to the DPA, Magellan shall deliver a final certification, in the form described therein, no later than 30 calendar days before the expiration of the Agreement.

AGREED TO:


FOR THE UNITED STATES ATTORNEY'S OFFICE FOR THE DISTRICT OF MASSACHUSETTS

Date: 4/27/26

LEAH B. FOLEY
United States Attorney

By:


MACKENZIE A. QUEENIN
Chief, Health Care Fraud Unit



LESLIE A. WRIGHT
Assistant United States Attorney

FOR MAGELLAN DIAGNOSTICS, INC.

Date: 4/29/26

By: 
EMERSON C. MOSER
SVP, General Counsel
Magellan Diagnostics, Inc.

Date: April 27, 2026

By: 
ADAM J. HOLLINGSWORTH
Counsel for Magellan Diagnostics, Inc.